It’s in the Genes

December 20, 2022

Dear [[firstname]],

Today we bring you our Option Trade of the Week, an idea generated by our trading team, for your consideration. But first, I would like to remind you that our proprietary 10K Strategy has generated average annual gains of 60% for the past five years in actual brokerage accounts (including all commissions) carried out for our subscribers.  In the difficult current year, our portfolios have suffered a 2.7@ loss which is significantly better than the 19.7% that the S&P 500 has lost so far in 2022.

You can learn every detail of how to carry out the 10K Strategy on your own for a grand total of $98. In addition, you will get a 14-day options tutorial that will give you a good grasp of the opportunities and dangers of trading options, our latest White Paper, access to several valuable reports, and four weeks of our Saturday Report which shows all the trades and positions of five actual options portfolios. An entire treasure trove of information on stock options.  Just Click Here, select Sign Up Now and use Coupon Code D21M to start a monthly subscription (and cancel the subscription if you don’t want to continue with the Terry’s Tips newsletter).

It’s in the Genes

Moderna (MRNA), the company of COVID vaccine fame, announced this week that a cancer vaccine, in combination with a Merck (MRK) drug, showed positive results in a trial on melanoma patients. The stock jumped 20% on the news but then pulled back amid the overall market swoon.

Oddly, the stock received a downgrade and a target price increase from the same analyst after the news. I guess he wants to cover his bets. But that reflects the opinion of the greater analyst community, where only half the recommendations are a buy or better. Moreover, the average target price is just $210, which is a mere 8.6% above Friday’s close. That’s closer than most stocks, meaning analysts will likely not hit the stock with damaging target price decreases to compensate for not lowering their target throughout the bear market. In other words, the target price is perfectly reasonable, unlike most stocks.

On the chart, MRNA had been trading sideways for a month amid an intermediate-term uptrend that pulled the shares 50% higher. But the big pop this week shot the stock up to its highest level since January. In addition, the shares pulled away from their rising 20-day moving average, a trendline the stock had been clinging to.

This trade is based on MRNA continuing to gain on the heels of its trial report. This is consistent with the options market, where out-of-the-money (OTM) calls are more expensive than equally OTM puts. Note also that the 20-day (blue line) sits above the strike of our spread’s short put at $175 (red line).  If you agree that MRNA will continue its rally – or at least remain atop the 20-day – consider the following trade that relies on the stock staying above $175 through expiration in five weeks:

Buy to Open the MRNA 20 Jan 170 put (MRNA230120P170)
Sell to Open the MRNA 20 Jan 175 put (MRNA230120P175) for a credit of $1.35 (selling a vertical)

This credit is $0.02 less than the mid-point price of the spread at Friday’s $193.29 close. Unless MRNA surges quickly, you should be able to get close to that price.

The commission on this trade should be no more than $1.30 per spread. Each spread would then yield $133.70. This trade reduces your buying power by $500, making your net investment $366.30 per spread ($500 – $133.70). If MRNA closes above $175 on Jan. 20, both options will expire worthless and your return on the spread would be 37% ($133.70/$366.30). 

Any questions?  Email

Testimonial of the Week

I have been a subscriber for about a year. I autotrade in 2 different accounts, all your strategies. I read everything you write on Saturdays. I love your happiness thoughts and everything else. I usually do not communicate at all but I had to tell you how well my accounts with you are doing compared to everything else. You are awesome. Keep up the good work. Thank you.

~ Maya

Thank you again for being a part of the Terry’s Tips newsletter.

Happy trading,